AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 396654
Drug: Pirenzepine (PRZ)
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PRZ) 75 mg/day for 10 days followed by 50 mg/day for 20 days
Trial: 396654
Drug: Carbenoxolone (CB)
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone (CB) 300 mg/day followed by 200 mg/day
Trial: 28600039
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of misoprostol vaginally every 12 hours after an 800-μg vaginal loading dose
Trial: 28600039
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of misoprostol sublingually every 12 hours after an 800-μg vaginal loading dose
Trial: 28600039
Drug: Sequential sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential sublingual misoprostol after a vaginal loading dose
Trial: 28600039
Drug: Sequential sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential sublingual misoprostol regimen
Trial: 31268872
Drug: Allopurinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (600 mg/day)
Trial: 19473601
Drug: HX575 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HX575 (100 IU/kg body weight, subcutaneous, three-times-weekly for 4 weeks)
Trial: 19473601
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta (100 IU/kg body weight, subcutaneous, three-times-weekly for 4 weeks)
Trial: 17978603
Drug: Renin‐angiotensin system‐blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin‐angiotensin system‐blocking agents
Trial: 17978603
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of other agents if needed to meet blood pressure goal
Trial: 11124759
Drug: Modified Sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Sham Feeding (MSF) with 38 g fat
Trial: 11124759
Drug: Control: Lunch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: Lunch with 38 g fat
Trial: 2691568
Drug: Intramuscular recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular recombinant interferon alpha‐2a (r‐IFN) at doses of 4.5 megaunits thrice weekly for 4 months
Trial: 31204839
Drug: Face-to-face (FTF)
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face (FTF) treatment, 1-week treatment
Trial: 31204839
Drug: FTF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTF treatment
Trial: 19011946
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative chemoradiation therapy (non-CRT)
Trial: 9084062
Drug: CI-988 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-988 (50 mg)
Trial: 9084062
Drug: CI-988 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-988 (100 mg)
Trial: 2410320
Drug: Dioctyl sodium
RxNorm normalized name: Dioctyl sodium sulfosuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctyl sodium sulfosuccinate (DSS) 100 mg three times daily for 4 days
Trial: 2410320
Drug: Dioctyl sodium
RxNorm normalized name: Dioctyl sodium sulfosuccinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctyl sodium sulfosuccinate (DSS) 100 mg three times daily for 7 days
Trial: 26890230
Drug: Mirror Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror Therapy (MT) combined with Neuromuscular Electrical Stimulation (NMES) and conventional physical therapy
Trial: 22069972
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) 3.5 mL intra-knee-articular injections
Trial: 22069972
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (SH) 2 mL intra-knee-articular injections
Trial: 19320670
Drug: Internet-based interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based interventions (IBI) for problem drinking; specific dosage and duration not mentioned.
Trial: 19320670
Drug: Check Your
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Check Your Drinking screener (IBI for problem drinkers); specific dosage and duration not mentioned.
Trial: 11907839
Drug: Methotrexate 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 0.25% gel
Trial: 9036910
Drug: Intra-articular triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular triamcinolone acetonide (3 injections at day 1, 8, and 22 over 4 weeks)
Trial: 112944
Drug: Intravenous protirelin
RxNorm normalized name: PROTIRELIN
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous protirelin (0.5 mg)
Trial: 112944
Drug: Niacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (2 mg)
Trial: 30937431
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (LDCT) screening beyond 5 years
Trial: 17678670
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training (n=7), twice a week for 6 weeks, including dumbbell bicep curls, wrist flexions, and wrist extensions
Trial: 12733373
Drug: Domestic intravenous
RxNorm normalized name: domestic cow dander extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domestic intravenous Turbutalin Sulfate
Trial: 9677793
Drug: Ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (30 mg as a priming dose and 90 mg infused over 24 hours)
Trial: 9677793
Drug: Tramadol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (100 mg + 300 mg)
Trial: 9677793
Drug: Buprenorphine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.3 mg + 0.9 mg)
Trial: 9677793
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ketorolac and buprenorphine (30 mg of K as priming dose and 60 + 0.6 mg in infusion)
Trial: 7837949
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg orally every 8 h for 36 h)
Trial: 3421264
Drug: Labetalol pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol pretreatment (20 mg IV followed by 10 mg increments up to 1 mg/kg)
Trial: 31914034
Drug: So-Cheong-Ryong-Tang (SCRT)
RxNorm normalized name: SO-101
DrugBank: SO-101 (DB05345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: So-Cheong-Ryong-Tang (SCRT) administered 3 times a day for 4 weeks
Trial: 22900583
Drug: Prasugrel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (10 mg) with Ritonavir (100 mg)
Trial: 22900583
Drug: Ritonavir (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (100 mg)
Trial: 21626525
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (24, 48, or 72 weeks)
Trial: 21626525
Drug: Variable therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable therapy (24, 48, or 72 weeks)
Trial: 21626525
Drug: IL28B type
RxNorm normalized name: adenovirus, type 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL28B type (CC, CT, TT)
Trial: 17239870
Drug: Phenazopyridine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazopyridine (200 mg)
Trial: 9484873
Drug: Grepafloxacin 200
RxNorm normalized name: grepafloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grepafloxacin 200 mg
Trial: 9484873
Drug: Grepafloxacin 400
RxNorm normalized name: grepafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grepafloxacin 400 mg
Trial: 10991830
Drug: Grepafloxacin 600
RxNorm normalized name: grepafloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grepafloxacin 600 mg
Trial: 29503217
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy-based pain management program
Trial: 27561981
Drug: Immediate postpartum
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate postpartum insertion of the etonogestrel-releasing contraceptive implant
Trial: 27561981
Drug: 6-week postpartum
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week postpartum insertion of the etonogestrel-releasing contraceptive implant
Trial: 25799024
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral Internet-based intervention, 2 weekly 45-minute sessions over 5 weeks (10 sessions total)
Trial: 12480038
Drug: Propafenone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone SR 425 mg twice daily
Trial: 12480038
Drug: Propafenone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone SR 325 mg twice daily
Trial: 14556870
Drug: Propafenone SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone SR 225 mg twice daily
Trial: 8836744
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly contact to equalize attention)
Trial: 1389953
Drug: Medifoxamine 300-1000
RxNorm normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medifoxamine 300-1000 mg
Trial: 1389953
Drug: Timolol 20
RxNorm normalized name: timolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 20 mg
Trial: 23067317
Drug: Levofloxacin-containing 7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing 7-day triple therapy (Levo triple)
Trial: 23067317
Drug: Standard sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sequential therapy (SST-10)
Trial: 23067317
Drug: Levofloxacin-containing sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin-containing sequential therapy (Levo-ST-10)
Trial: 18630547
Drug: Acupuncture compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture compound anesthesia (electroacupuncture combined with intramuscular injection of Pethidine)
Trial: 18630547
Drug: Simple Pethidine
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple Pethidine (intramuscular injection)
Trial: 19186718
Drug: Acupuncture compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture compound anesthesia
Trial: 16195767
Drug: Lipid Replacement
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid Replacement Therapy plus antioxidants
Trial: 10363733
Drug: Sparfloxacin (400-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (400-mg loading dose followed by 200 mg once daily)
Trial: 1778879
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g ceftriaxone iv once daily for three days
Trial: 1778879
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g ceftriaxone iv once daily for three days
Trial: 1778879
Drug: Chloramphenicol 3
RxNorm normalized name: chloramphenicol 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 3 g daily in divided doses for two days followed by 2 g daily for 12 days
Trial: 6980231
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg oxaprozin (600 mg twice daily)
Trial: 6980231
Drug: 3900 mg
RxNorm normalized name: aspirin 3900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3900 mg aspirin (975 mg four times a day)
Trial: 20537469
Drug: Normal compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal compression pressure garment therapy
Trial: 20537469
Drug: Low compression
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low compression pressure garment therapy
Trial: 14693987
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol consumption (4 glasses of whisky, 40 g ethanol daily)
Trial: 12563776
Drug: Artesunate 6
RxNorm normalized name: artesunate 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate 6 mg/kg once every 2 weeks for 4 times
Trial: 8547549
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl (55 micrograms/kg) anesthesia
Trial: 8547549
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl (55 micrograms/kg) anesthesia + thoracic epidural analgesia
Trial: 8547549
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl (15 micrograms/kg) anesthesia + thoracic epidural analgesia
Trial: 2230578
Drug: HRCh (local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRCh (local ultra‐high frequency hyperthermia in combination with radiotherapy and chemotherapy)
Trial: 2230578
Drug: RCh (radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCh (radiotherapy and chemotherapy)
Trial: 773416
Drug: Prophylactic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic factor VIII therapy (infusions given once weekly to achieve a post-infusion plasma concentration of at least 0.25 I.U./ml)
Trial: 28527129
Drug: Plerixafor (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (240 µg/kg/day) + G‐CSF (filgrastim, 400 µg/m2/day) for 4 days
Trial: 28527129
Drug: G‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF alone (G group)
Trial: 25125385
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) plus Hydroxychloroquine (HCQ)
Trial: 20174466
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) alone
Trial: 25125385
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) plus Clopidogrel (CLOP)
Trial: 25125385
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) alone or in combination with ASA
Trial: 21562238
Drug: Zinc supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplement (15 mg zinc as ZnSO4)
Trial: 21562238
Drug: Control (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (200 g/d of wheat bread fortified with iron and folic acid, no zinc)
Trial: 21562238
Drug: Moderate zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate zinc fortification (7.5 mg zinc as ZnO)
Trial: 21562238
Drug: High zinc
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High zinc fortification (15 mg zinc as ZnO)
Trial: 19221190
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium carbonate and 400 IU of vitamin D(3) daily)
Trial: 12678187
Drug: Venoruton (hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoruton (hydroxyethyl rutosides) 1 g twice daily for 3 days (2 days before the flight and the day of the flight)
Trial: 7981011
Drug: Quinapril 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 2.5 mg p.o.
Trial: 24067395
Drug: Intravenous myo-inositol
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous myo-inositol at 60 mg/kg
Trial: 24067395
Drug: Intravenous myo-inositol
RxNorm normalized name: myo-inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous myo-inositol at 120 mg/kg
Trial: 19515113
Drug: Prescription drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drugs and dietary supplements
Trial: 19515113
Drug: Prescription drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription drugs
Trial: 19515113
Drug: Estrogen preparations
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen preparations
Trial: 19515113
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs, thyroid drugs, and estrogens
Trial: 19515113
Drug: Drugs for
RxNorm normalized name: DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for diabetes mellitus
Trial: 11275667
Drug: Modified Atraumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Atraumatic Restorative Treatment (ART)
Trial: 29925421
Drug: S-amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-amlodipine (2.5 mg) plus chlorthalidone (25 mg)
Trial: 29925421
Drug: S-amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-amlodipine (2.5 mg) plus telmisartan (40 mg)
Trial: 26791992
Drug: Computerized medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized medication reviews conducted by expert teams
Trial: 20119816
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg, 3 times daily) with dietary treatment
Trial: 20119816
Drug: Dietary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary treatment only
Trial: 16460484
Drug: rabeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole, amoxicillin, and minocycline
Trial: 16460484
Drug: rabeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole, amoxicillin, and clarithromycin
Trial: 7803769
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor scintigraphy with 111In-labeled octreotide
Trial: 3378560
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with levodopa and bromocriptine
Trial: 8375429
Drug: Bromocriptine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine monotherapy
Trial: 5811680
Drug: Fluid therapy
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid therapy with 2 litres of Ringer‐lactate solution transfused in one hour during surgery.
Trial: 5811680
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 2 litres of Ringer‐lactate solution transfused in one hour.
Trial: 31625118
Drug: No beta-blocker
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No beta-blocker use
Trial: 27753739
Drug: Rutoside (600-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rutoside (600-1200 mg.d) and hydrolytic enzymes (540-1080 mg.d bromelain, 288-576 mg.d trypsin)
Trial: 18305926
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of MDMA and ethanol
Trial: 3661647
Drug: Q-switched Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched Nd:YAG laser treatment
Trial: 23548852
Drug: Multidisciplinary stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary stress treatment programme (9 sessions over 3 months, including mindfulness-based stress reduction course for 2 hours a week over 8 weeks)
Trial: 21040559
Drug: Multidisciplinary stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary stress treatment programme
Trial: 23548852
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control group (12 consultations with a psychologist)
Trial: 21617185
Drug: Metreleptin administration
RxNorm normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metreleptin administration for 16 weeks
Trial: 14566003
Drug: E5564, 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5564, 3.5 mg/h x 72 h
Trial: 14566003
Drug: E5564, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5564, 3 mg/h x 4 h
Trial: 14566003
Drug: E5564, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5564, 0.5 mg/h x 4 h
Trial: 14566003
Drug: E5564, 252
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5564, 252 mg after 72-h infusion
Trial: 2893190
Drug: Short-course prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-course prednisone therapy (60 mg/m2 per 24 h until proteinuria disappeared for 3 days, then 40 mg/m2 per 48 h until complete remission)
Trial: 2893190
Drug: Standard prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard prednisone therapy (60 mg/m2 per 24 h for 4 weeks, then 40 mg/m2 per 48 h for 4 weeks)